Article

Bcl-2 family proteins as therapeutic targets.

The Walter and Eliza Hall Institute for Medical Research, 1G Royal Parade, Parkville, Victoria, Australia.
Current pharmaceutical design (Impact Factor: 4.41). 09/2010; 16(28):3132-48. DOI: 10.2174/138161210793292429
Source: PubMed

ABSTRACT The mitochondrion provides the stage for the interplay of molecular interactions that regulate apoptosis via the intrinsic pathway. The release of apoptogenic factors from this compartment constitutes a critical juncture in this apoptotic pathway. Regulation of the integrity of the outer mitochondrial membrane (OMM) is the task of the Bcl-2 family of proteins. A network of interactions between the various subgroups of the family decides the apoptotic fate of a cell and, as such, an imbalance within this network can lead to a variety of disease states. In particular, over-expression of pro-survival Bcl-2 family proteins is a hallmark of many cancers. Here we discuss recent advances in targeting the Bcl-2 family with both peptides and small molecules.

0 Bookmarks
 · 
92 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: The Gram-negative bacterium Vibrio vulnificus produces hemolysin (VvhA), which induces cytotoxicity in mammalian cells. However, our understanding of the cytotoxic mechanism and the modes of action of VvhA are still fragmentary and incomplete. The recombinant protein (r) VvhA (50 pg/ml) significantly induces necrotic cell death and apoptosis in human intestinal epithelial (INT-407) cells. The apoptotic cell death induced by rVvhA is highly susceptible to the sequestration of cholesterol by methyl-β-cyclodextrin, whereas for necrotic cell death, this shows a marginal effect. We found that rVvhA induces the aggregation of lipid raft components coupled with NADPH oxidase enzymes, in which rVvhA increased the interaction of NADPH oxidase 2 (NOX2, gp91(phox)) with a cytosolic protein NCF1 (p47(phox)) to facilitate the production of reactive oxygen species (ROS). rVvhA uniquely stimulated a conventional PKC isoform PKCα and induced the phosphorylation of both ERK and JNK, which are responsible for the activation of transcription factor NF-κB. rVvhA induced an NF-κB-dependent imbalance of the Bcl-2/Bax ratio, the release of mitochondrial cytochrome c, and caspase-3/-9 activation during its promotion of apoptotic cell death. In addition, rVvhA has the ability to inhibit the expression of cell cycle-related proteins, such as CDK2, CDK4, cyclin D1, and cyclin E. These results demonstrate that rVvhA induces NF-κB-dependent mitochondrial cell death via lipid raft-mediated ROS production by the distinct activation of PKCα and ERK/JNK in intestinal epithelial cells.
    Cell Death & Disease 02/2015; 6(2):1655. DOI:10.1038/cddis.2015.19 · 5.18 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Aim: Hydroxybenzoic acids are one of the major classes of phenolic compounds and are widely distributed in the phytochemicals of various plants. The aim of this study is to assess the efficacy of 2-, 3-and 4-hydroxybenzoate calcium (HBCa) complexes on HT-1080 cells and examine their anti-proliferative and pro-apoptotic effects in relation to 2-acetylbenzoic acid (2-ABA), or aspirin. Materials and Methods: The cytotoxicity of HBCa complexes was analysed in HT-1080 cells by MTT assay. Immunochemical and morphological assessment techniques were conducted to detect apoptosis, while Western blot was used to measure the expression of pro-and anti-apoptotic proteins. Results: The current in vitro study showed that HBCa complexes exert their cytotoxic activity in a concentration and chemical structure-dependent manner. 4-HBCa showed more potency than 3-HBCa, 2-ABA and 2-HBCa analogues. HBCa complexes inhibited cell proliferation, inducing apoptosis and cell cycle arrest at G0/G1 in human fibrosarcoma HT-1080. In addition, HBCa complexes modulated anti-apoptotic protein Bcl-2 and the induction of Bax, p53 and caspases-3 in favour of apoptosis. Conclusion: These results suggest that the apoptotic effects of the HBCa complexes are driven via the intrinsic apoptotic pathway which is regulated, at least to some extent, by the relative expression of Bcl-2 family proteins. The increased potency of 4-HBCa compared to 2-HBCa, 3-HBCa and 2-ABA provides a rationale for the continued exploration of these analogues as anti-cancer agents. «L'attività anti-proliferativa e pro-apoptotica dei complessi di idrossibenzoato di calcio in cellule di fibrosarcoma umano HT-1080» Riassunto. Scopo: Gli acidi idrossibenzoici sono una delle principali classi di composti fenolici e sono ampia-mente presenti tra i fitochimici di piante diverse. Lo scopo di questo studio è quello di valutare l'efficacia dei complessi di 2-, 3-e 4-idrossibenzoato di calcio (HBCa) su cellule HT-1080 ed esaminare i loro effetti anti-proliferativi e pro-apoptotici in relazione all'acido 2-acetilbenzoico (2-ABA) o aspirina. Materiali e Metodi: La citotossicità dei complessi HBCa è stata analizzata in cellule HT-1080 mediante saggio MTT. Per rilevare l'apoptosi sono state utilizzate tecniche di valutazione immunochimica e morfologica, mentre il Western blot è stato utilizzato per misurare l'espressione di proteine pro-e anti-apoptotiche. Risultati: L'attuale studio in vitro ha dimostrato che i complessi HBCa esercitano la loro attività citotossica in maniera dipendente da concentrazione e struttura chimica. 4-HBCa ha mostrato maggiore efficacia degli analoghi 3-HBCa, 2-ABA e 2-HBCa. I complessi HBCa inibiscono la proliferazione cellulare, inducono apoptosi e arrestano il ciclo cellulare in G0/G1 in fibrosarcoma umano HT-1080. Inoltre, i complessi HBCa modulano la proteina anti-apoptotica Bcl-2 e determinano l'induzione di Bax, p53 e caspasi-3 in favore dell'apoptosi. Conclusione:
  • [Show abstract] [Hide abstract]
    ABSTRACT: In the past 20 years, cancer therapeutics has undergone a paradigm shift away from the traditional cytotoxic drugs towards the targeting of proteins intimately involved in driving the cancer phenotype. The poster child for this alternative approach to the treatment of cancer is imatinib, a small-molecule kinase inhibitor designed to target chronic myeloid leukaemia driven by the BCR-ABL translocation in a defined patient population. The improvement in survival achieved by treatment of this patient cohort with imatinib is impressive. Thus, the aim is to provide efficacy but with low toxicity. The role of the medicinal chemist in oncology drug discovery is now closely aligned with the role in most other therapeutic areas with high-throughput and/or fragment-based screening, structure-based design, selectivity, pharmacokinetic optimisation and pharmacodynamic biomarker modulation, all playing a familiar part in the process. In this chapter, we selected four areas in which compounds are either approved drugs or in clinical trials. These are chaperone inhibitors, kinase inhibitors, histone deacetylase inhibitors and inhibitors of protein-protein interactions. Even within these areas, we have been selective, particularly for kinase inhibitors, and our aim has been to exemplify newer approaches and novel aspects of medicinal chemistry. © 2015 Elsevier B.V. All rights reserved.